Support structures for dermal regeneration are composed of biodegradable and bioresorbable polymers, animal skin or tendons, or are bacteria products. The use of such materials is controversial due to their low efficiency. An important area within tissue engineering is the application of multipotent mesenchymal stromal cells (MSCs) to reparative surgery. The combined use of biodegradable membranes with stem cell therapy may lead to promising results for patients undergoing unsuccessful conven- tional treatments. Thus, the aim of this study was to test the efficacy of using membranes composed of anionic collagen with or without the addition of hyaluronicacid (HA) as a substrate for adhesion and in vitro differentiation of bone marrow-derived canine MSCs. The benefit of basic fibroblast growth factor (bFGF) on the differentiation of cells in culture was also tested. MSCs were collected from dog bone marrow, isolated and grown on collagen scaffolds with or without HA. Cell viability, proliferation rate, and cellular toxicity were analyzed after 7 days. The cultured cells showed uniform growth and morphological characteristics of undifferentiated MSCs, which demonstrated that MSCs successfully adapted to the culture conditions established by collagen scaffolds with or without HA. This demonstrates that such scaffolds are promising for applications to tissue regeneration. bFGF significantly increased the proliferative rate of MSCs by 63% when compared to groups without the addition of the growth factor. However, the addition of bFGF becomes limiting, since it has an inhibitory effect at high concentrations in culture medium.
The results obtained at this work show that cashew apple juice is a suitable substrate for the growth of Strep- tococus zooepidemicus and the production of oligomers of HA. Furthermore, cashew apple juice supplemented with yeast extract is a proper substitute for the conventional me- dium BHI used for inoculum propagation, which is expen- sive and has a risk for contamination. It was observed that the composition of the culture medium as well as oxygen supply influenced the microbial production of HA (concen- tration and viscosity), highest concentrations were obtained when the fermentation was carried out under aeration. The hyaluronicacid viscosity increased when cashew apple juice was supplemented with 60 g/L of yeast extract. The potentialities of CAJY medium are evident, with the advan- tages that BHI did not need to be added, resulting in a fer- mentation medium without risk of cross-species viral and other infection agent. These results point out to a straight and safe process to produce HA oligomers suitable to im- portant medical applications as a high value-added product. Nowadays, most of methods for production of HA oligo- mers involve enzymatic digestion or sonication of poly- meric HA followed by purification of fractions.
Braz. J. of Develop., Curitiba, v. 6, n. 7, p. 49962-49979, jul. 2020 . ISSN 2525-8761 In the glucose and sugarcane molasses media, glutamine exhibited non-significant but positive effects at the tested concentrations (Fig. 1) due to the amino acid acting as the amino donor group to UDP-N-acetylglucosamine formation , limiting hyaluronicacid precursor synthesis . The determination coefficient (R²) for fermentation using molasses by fractional factorial design was 0.8485, explaining the 84.85 % response variability. The desirability function was used to find the optimal conditions for hyaluronicacid production. Under this condition (glutamine at 4 g·L -1 ), the
Abstract: Objectives: We report our experience with subureteral submucosal injection therapy for vesicoureteral reflux and determine the safety and efficacy in patients treated with dextranomer/ hyaluronicacid co-polymer. Background: Vesicoureteral reflux affects 1% of children and increases the chances of urinary tract infection, pyelonephritis, hypertension and chronic renal insufficiency. The aim of identifying and treating vesicoureteral reflux in children is to prevent occurrence of long term complications. Method: A total of sixty three patients aged between 1-21 years with grade III – V vesicoureteral reflux, who had failed on conservative treatment were considered for this study during February 2004 to May 2012.Vesicoureteral reflux was diagnosed by voiding cysto-urethrogram (VCUG). They underwent subureteral injection of dextranomer/ hyaluronicacid co-polymer. Results: Among the sixty three patients treated, 51(81%) were cured with single injection while a second injection raised the cure rate to 60(95%). Conclusion: The minimally invasive treatment of vesicoureteral reflux with deflux (dextranomer/ hyaluronicacid co-polymer) is an effective alternative procedure to open surgical technique requiring minimal operating time with low morbidity.
Objective: Polymyositis (PM) is a rare systemic idio- pathic inflammatory myopathy. Hyaluronicacid (HA) is closely linked to inflammatory cellular reactions and disease activity. Increased serum levels of HA have been reported in several inflammatory diseases, but curren- tly, there are no studies analysing the HA in PM. Thus, clinical association of HA with PM in patients was de- termined in the present study.
Hyaluronicacid (HA), an important com- ponent of the extracellular matrix, is a large glycosaminoglycan composed of repeating units of β-D-glucuronic acid and N–acetyl-D-glucosamine. HA plays an important role in tissue development, cell migration, cell proliferation and inlammation (Inoue and Katakami 1993, Gomes et al. 2004). HA is increased in the tear luid when corneal epithelium erosion is present, and may play an important role in corneal epithelium wound healing (Oya et al. 1995, Miyauchi et al. 1996). Tear luid consistency (gel-like) can be attributed to HA (Itano et al. 1999). Another important characteristic of this GAG is its chemical structure that can attract ions and water due to a negative charge density (Frescura et al. 1994, Yoshida et al. 1996).
The aim of this project is to develop a new hydrogel made of Dextrin (Dex), Hyaluronicacid (HA) and Extracellular matrix (ECM) from Small Intestine Submucosa (SIS), using different types of HA, mixed different proportions. In this study, HA and Dex were oxidized by sodium periodate to create aldehyde functional groups, which could be cross-linked by Adipic Acid Dihidrazide (ADH). Their characterization was performed based on gelation period and degradation rate. In addition, cell viability tests were performed through a Resazurin assay, a MTS assay and Live and Dead (LD) using osteoblastic cell line MC3T3 calvaria from mouse. Results showed a low gelation time for all the hydrogels and low degradation rates for mixed hydrogels with high contents of high molecular weight (MW) HA. The degradation tests demonstrated that the selected hydrogel could maintain the gel matrix over 70 days.
ABSTRACT - Purpose: To compare the effect of hyaluronicacid (HA) and of AG on the healing of intestine wounds. Methods: The semi-purified extract of the eggs of the mollusc was obtained by fractionation with ammonium sulfate and purification for ion-exchange chromatography. The obtained galactans were eluted in water (neutral galactan) and in 0.1 and 0.2M NaCl (acidic galactans). The in vivo study was performed with 45 “Wistar” rats, separated in three groups (n=15). Solutions containing HA 1%, GA 1% or saline solution 0,9%, was placed topically on the sutures of wounds in the small intestine of the rats. After 05, 10 and 21 days the animals were sacrificed and biopsy of the healing tissue was done. Results: The hystologic grading was more significant for HA and AG groups when compared to the group C. AG stimulated the appearance of macrophages, giant cells and increase in the concentration of collagen in the area of the wound when compared to HA. Conclusion: The topical use of GA in intestinal wounds promoted the anticipation of events that are important in the wound healing.
In this paper, hyaluronicacid (HA) was evaluated as a possible reti- nal gene therapy vector. HA is a biocompatible, non-toxic, non- immunogenic, non-in ﬂammatory anionic biopolymer that has been widely used in various biomedical applications . Multiple studies on the biological function of HA have revealed that there is a strong rela- tionship between the presence of HA and the migration and prolifera- tion of cells as well as an involvement in wound healing, cell motility, angiogenesis, and extracellular matrix formation. Another important feature of HA for its use as a vector of therapeutic genes is the ability to interact with various cell receptors . The negatively charged car- boxyl group of HA is responsible for the interaction with membrane re- ceptors allowing the connection with HA .
The age-standardized prevalence of knee osteoarthritis (OA) is 3.8%, making OA one of the leading causes of global disability . Intra-articular (IA) injection of hyaluronicacid (HA) has been recommended to alleviate pain and improve joint function in patients with knee OA . Chondroprotective and analgesic properties inherent to HA  suggest that HA can delay total knee replacement (TKR) surgery , a treatment popular enough that it has become a key driver of health care costs . It is estimated that 54% of knee OA patients will receive TKR over their lifetime under current guidelines; the current trend of expanding indications for TKR suggests that there may be a 29% increase in lifetime direct medical costs attributable to TKR among knee OA patients .
Endometriosis is defined as the presence of endometrial tissue outside the uterine, which may affect nearly 60% of women in reproductive age. Deep infiltrating endometriosis (DIE) defined as an endometriotic lesion penetrating into the retroperitoneal space or the wall of the pelvic organs to a depth of at least 5 mm represents the most diagnostic challenge. Herein, we reported the use of hyaluronicacid (HA)-modified magnetic iron oxide nanoparticles (HA-Fe 3 O 4 NPs) for
Cancer is the leading cause of death in the world. Cancer research is continuously growing aiming to achieve more efficient therapies and early diagnostics. Different challenges arise, concerning the development of efficient drug delivery systems compared to conventional therapies, such as chemotherapy. New formulations promoting a controlled drug distribution, potentiating selective and efficient pharmaceutical actions, have been developed. Nanogels, produced by self-assembly of chemical modified natural polymers, are suitable for this purpose since they are able to encapsulate the hydrophobic drugs, physically or chemically. The use of labile linkages, to stabilize drugs, allows a selective drug release, such as pH-sensitive hydrazone. Doxorubicin is a drug currently used in chemotherapy, however, a major drawback remains its toxicity to healthy tissues, when used in high dosages, and the development of multi-drug resistance during prolonged treatment. Doxorubicin can be conjugated with hyaluronicacid, a natural polymer abundant in the human body, via hydrazone or amide linkages. The main goals of this work consist in the development of hyaluronicacid-based nanogels for cancer therapy with doxorubicin, as well as the incorporation of -Fe 2 O 3 into the nanogels to develop a
Osteoarthritis (OA) is the most common form of chro- nic arthritis worldwide. The etiology of pain in os- teoarthritis is multifactoral, and includes mechanical and inflammatory processes. The use of intra-articular viscosupplementation in the nonoperative manage- ment of patients with osteoarthritis has become quite popular. Recent clinical data have demonstrated that the anti-inflammatory and chondroprotective actions of hyaluronicacid viscosupplementation reduce pain, from 4 to 14 weeks after injection, while improving pa- tient function. Viscosupplements are comparable in ef- ficacy to systemic forms of active intervention, with more local reactions but fewer systemic adverse events, and hyaluronicacid has more prolonged effects than IA corticosteroids. Although several randomized con- trolled trials have established the efficacy of this treat- ment modality, additional high quality randomized control studies with appropriate comparison are still required to clearly define the role of intra-articular hya- luronic acid injections in the treatment of osteoarthri- tis. We review the basic science and development of viscosupplementation and discuss the mounting evi- dence in support of its efficacy and safety profile. Keywords: Viscosupplementation; Osteoarthritis; Knee; Pain; Hyaluronicacid
Although hallux valgus is a frequently seen musculoskeletal disorder in general, its treatment protocolhas not yet been clariied. A consensus has not been reached on several surgi- cal techniques and their rates of success [11,12].Conservative treatment options which are widely preferred, are limited. In our study, VAS values and daily analgesic needs of patients decreased and walking distance and walking time increased signiicantly one month ater the hyaluronicacid injection. There were no signiicant diferences between the irst and third months’ mean values of walking time and distance ater injection, relecting unchanged positive efects of administra- tion. Also, since these indings are similar ater three months of the hyaluronicacid delivery,the possibility of a placebo ef- fect is minimized.Similar to our results, several studiesoirst metatarsophalangeal joint osteoarthritishave reported that HA injections resulted in statistically signiicant reductions in patients’symptoms [13,14].Pons et al. compared the efec- tiveness of HAand triamcinolone injections in irst metatarso- phalangeal joint osteoarthritis in 37 patients, and found that both treatments were successfulin terms of pain at rest or with palpation and pain on passive mobilization, without any signiicant diferences between groups .Petrella et al.  assessed the eicacy of HA injections into the irst MTP joint in golfers toe patients who reported osteoarthritis-associated pain, loss of MTP joint ROM, and disability that interfered with golf participation. They reported that HA injection was signii- cantly efective for pain tolerance.However, the results of thethesestudies could not be conirmed by placebo-controlled randomized trials.
Hyaluronicacid (HA) is a hydrated gel and comprises repeating units of glucuronic acid and N-acetylglucosamine. Production and recovery of HA has gained great importance due to its vast clinical applications. In pursuit of obtaining highly pure HA, we have developed a fed-batch fermentation process using Streptococcus zooepidemicus in a 25 L bioreactor that resulted in a maximum yield of 2.3 g/L HA. In addition, we have devised an efficient method for separation and recovery of hyaluronicacid from a highly viscous broth by treating with trichloroacetic acid (0.1%) and charcoal (1-2%), passing through filtration (0 .45 μm) and ultrafiltration that resulted in recovery of 72.2% of clinical grade HA with molecular weight of 2.5×10 6 Da. We have also
Materials and methods: A systematic review of the lit- erature was carried out within MEDLINE (via PubMed), Web of Science, Scopus and Cochrane Cen- tral Register of Controlled Trials (CENTRAL) databa ses, using the keywords (MeSH words): “hip osteoarthri- tis”, “glucocorticoid”, “corticosteroid”, “corticoid”, “hyaluronicacid” and “viscosupplementation”. Two in- dependent authors applied inclusion and exclusion cri- teria, selecting randomized clinical trials with direct comparison between intra-articular injection of GC and HA in patients with HO.